The spliceosome catalyses pre-mRNA splicing and is assembled by recruitment of U1 and U2 small nuclear (sn)RNPs to the 5′ splice site and branch site, respectively, of the pre-mRNA intron, followed by integration of the preformed U4/U6.U5 tri-snRNP 1 . This generates the spliceosomal B complex, and after extensive RNP rearrangements, the pre-catalytic B act complex is formed (Extended Data Fig. 1a ). The latter is converted into the catalytically active B* complex by RNA helicase PRP2 (refs 2,3). During activation, a catalytic RNA-RNA network that resembles the catalytic core of group II self-splicing introns [4] [5] [6] , as well as the spliceosome's active site, are established. The B* complex catalyses step one of splicing, in which the branch site adenosine (BS-A) carries out a nucleophilic attack at the 5′ splice site. This yields the cleaved 5′ exon and the lariat-3′ exon, in which the 5′ end of the intron is covalently attached to the BS-A, forming a branched intron structure. Concomitantly the spliceosomal C complex is formed. The branched intron region must be displaced from the catalytic centre of the spliceosome after step one to allow juxtapositioning of the step-two reactants, the 3′ -OH of the 5′ exon (the nucleophile for step two) and the 3′ splice site. This remodelling is catalysed by RNA helicase PRP16 and leads to the C* complex 7, 8 . The latter catalyses step two, during which mRNA and the spliced-out intron are generated. Efficient catalysis of step two requires additional proteins, including SLU7, PRP18 and PRP22 (refs 9-13). However, the precise nature and dynamics of many spliceosome structural rearrangements, especially those occurring just before or during step two, remain unclear.
The spliceosome catalyses pre-mRNA splicing and is assembled by recruitment of U1 and U2 small nuclear (sn)RNPs to the 5′ splice site and branch site, respectively, of the pre-mRNA intron, followed by integration of the preformed U4/U6.U5 tri-snRNP 1 . This generates the spliceosomal B complex, and after extensive RNP rearrangements, the pre-catalytic B act complex is formed (Extended Data Fig. 1a ). The latter is converted into the catalytically active B* complex by RNA helicase PRP2 (refs 2,3). During activation, a catalytic RNA-RNA network that resembles the catalytic core of group II self-splicing introns [4] [5] [6] , as well as the spliceosome's active site, are established. The B* complex catalyses step one of splicing, in which the branch site adenosine (BS-A) carries out a nucleophilic attack at the 5′ splice site. This yields the cleaved 5′ exon and the lariat-3′ exon, in which the 5′ end of the intron is covalently attached to the BS-A, forming a branched intron structure. Concomitantly the spliceosomal C complex is formed. The branched intron region must be displaced from the catalytic centre of the spliceosome after step one to allow juxtapositioning of the step-two reactants, the 3′ -OH of the 5′ exon (the nucleophile for step two) and the 3′ splice site. This remodelling is catalysed by RNA helicase PRP16 and leads to the C* complex 7, 8 . The latter catalyses step two, during which mRNA and the spliced-out intron are generated. Efficient catalysis of step two requires additional proteins, including SLU7, PRP18 and PRP22 (refs 9-13) . However, the precise nature and dynamics of many spliceosome structural rearrangements, especially those occurring just before or during step two, remain unclear.
Cryo-electron microscopy (cryo-EM) of a post-step-two intron-lariat spliceosome (ILS) from Schizosaccharomyces pombe provided the first molecular insight into the architecture of the spliceosomal catalytic RNP core 5, 14 . Cryo-EM structures revealing the molecular architecture of the Saccharomyces cerevisiae and human U4/U6.U5 tri-snRNPs, and more recently of the S. cerevisiae B act and C spliceosomal complexes, have also been reported [15] [16] [17] [18] [19] [20] [21] [22] . However, to our knowledge, no high-resolution structures of human spliceosomal complexes are currently available. Here we report a 3D cryo-EM structure of a human spliceosomal C complex stalled after PRP16 action but before catalytic step two, which together with protein crosslinking, allows us to determine the spatial organization of its protein and RNA components.
Overview of the C* spliceosome structure
By lowering the pH of the in vitro splicing reaction, we were able to affinity-purify human spliceosomal complexes that were stalled before step two of splicing but after the action of PRP16 (denoted C* ) (Extended Data Fig. 1) , and shown by chase experiments to be functional (Extended Data Fig. 1 ). The 3D structure of the human C* complex was determined by cryo-EM, with an overall resolution of 5.9 Å and approximately 4.5 Å in areas of the catalytic RNP core (Extended Data Fig. 2) . A pseudo-atomic model was built for the more stable part of C* , where the resolution sufficed for clear identification of structured protein domains and double-stranded RNA elements, allowing us to fit known X-ray structures or homology models of structured regions of C* components into the EM density map (Fig. 1 A comparison of the overall structure of the human C* complex with that of the S. cerevisiae B act or C complex, and S. pombe ILS, reveals that the central domains of all four complexes possess similar size (approximately 20 × 12 nm) and morphology 14, [19] [20] [21] [22] . Like in the yeast spliceosomes, the lower central domain of C* contains U5 snRNP components, that is, the U5 snRNA, PRP8, SNU114, and U5-40K proteins, and the U5 Sm core (Fig. 1b, c) . Furthermore, the catalytic U2-U6 RNA structural element of the spliceosome (Fig. 2) , together with the U6 ACAGA box/intron helix, is docked in a similar manner into the active site region of PRP8 (ref. 23) (Extended Data Fig. 3 ). The positions of the U6 5′ stem-loop (close to the U5 Sm core) and of U2/U6 helix II (at the upper part of the main body) are also conserved, probably owing to their stabilization by similar sets of proteins (Extended Data Figs 3 and 4). For example, the human G10 protein interacts like its yeast counterpart (Bud31) with U6 snRNA close to the U6 5′ stemloop and anchors it to the PRP8 NTD1 domain (Extended Data Fig. 4 ).
While individual homologues of the yeast Cwc2 and Ecm2 proteins are absent in humans, the human RBM22 protein shares homology with both yeast Cwc2 and Ecm2, suggesting it is a fused version of both proteins 24 . Indeed, some regions of human RBM22 that are homologous to regions of the S. cerevisiae Cwc2 and Ecm2 proteins, are located in similar positions near the U6 internal stem loop (ISL) in the human C* complex and the S. cerevisiae C complex (Extended Data Fig. 4) . Thus, spliceosomal protein domains conserved in humans and yeast perform a similar function (that is, stabilizing critical snRNA structures), but are organized in a different manner in higher eukaryotes.
Like their orthologues in the yeast spliceosomes, the human HAT 25 (half a TPR) proteins SYF1 (also known as XAB2) and SYF3 (also known as CRNKL1) form long, curved α -helical solenoids that cross one another close to U2/U6 helix II (Fig. 1, Extended Data Fig. 5a, b) . Moreover, α -helical elements of human SYF2 (GCIP p29) share an interface with SYF3 and U6 snRNA upstream of U2/U6 helix II (Extended Data Fig. 5 ). The N-terminal HAT repeats of SYF1 share a large interface with the aquarius protein, located at an equivalent position at the top of the C* and ILS complexes, and extend to the nearby U2 Sm core domain, with its attached U2-A′ and U2-B′ ′ proteins (Fig. 1, Extended Data Fig. 5d, e) . SPF27, the C-terminal part of CDC5 and four copies of PRP19 form a helical bundle that fits into the elongated density element at the side of the C* main body, and is at an equivalent position in the S. pombe ILS (Fig. 1, Extended Data  Fig. 5a ).
Structure of U2-U6 catalytic RNP core
Consistent with previous biochemical studies 26 , the catalytic centre of the human C* complex contains a three-helical junction and is highly similar to the catalytic centre of the S. cerevisiae C complex. Indeed, the structure of the catalytic U2-U6 RNA of the latter fits well, with some adjustments, into an RNA-shaped element in our C* model (Figs 1c and 2, Extended Data Fig. 6a, b) . The approximately 4.5 Å resolution in this part of the C* complex allows the unambiguous placement of the loop and kinked stem of the U6 ISL, the two U2/U6 helices Ia and Ib (which are stacked on each other), and the sharp turn separating the ACAGA box helix of U6 snRNA and U2/U6 helix Ia (Fig. 2 , Extended Data Fig. 6a, b) . The topography of U6 nucleotides U74 and G72, and of A53 and G54, is such that they could potentially coordinate Mg 2+ ions 1 and 2 (which we cannot unambiguously discern at 4.5 Å resolution), respectively. This is consistent with biochemical studies showing metal ion coordination of the corresponding nucleotides in yeast U6 (ref. 27) . The similarity between the C and C* catalytic centres is also underscored by the conservation of protein-RNA interactions in the catalytic RNP core (Extended Data Figs 3b-f and 5b).
Following catalytic step one, the cleaved 5′ exon remains tightly bound to the spliceosome. In C* , the 3′ -terminal nucleotides of the 5′ exon, including the 3′ -OH of the exon (the step two nucleophile), are located close to the catalytic centre, with the 3′ hydroxyl close to the putative position of the Mg 2+ ion 1 (Fig. 2, Extended Data  Fig. 6f ). Exon nucleotides − 1 to − 3 are base-paired with U5 loop 
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nucleotides U40 to U42 (Extended Data Fig. 6f) , consistent with previous studies 28, 29 . We can trace an additional nine nucleotides of the exon RNA, which thread through a narrow tunnel between the linker region of the PRP8 reverse transcriptase/endonuclease (RT/En) domain and the PRP8 NTD1 domain, and then pass along the rearranged hairpin loop from the linker regions of PRP8 (the so-called switch loop) and the MA3 domain of CWC22 (Extended Data Fig. 7a, c) . The 20 N-terminal amino acids of SRm300 are juxtaposed with the PRP8 switch loop (Extended Data Fig. 7a, c) , similar to its probable yeast counterpart, Cwc21, in the C complex 21, 22 . Thus, this conserved N-terminal region of SRm300, together with the switch loop, probably plays an evolutionarily conserved role in stabilizing the 5′ exon during splicing catalysis.
CWC22 straddles the exon binding channel, with its MA3 domain bound to the PRP8 RT/En domain and its N-terminal MIF4G domain attached to domain 1 of SNU114, as well as to the helicase eIF4AIII (Extended Data Fig. 7 ). eIF4AIII is located close to the likely position of nucleotides − 20 to − 25 of the 5′ exon (Extended Data Fig. 7b ) and is part of the exon junction complex (EJC) that is deposited at a later stage 20-24 nucleotides upstream of the exon-exon junction of spliced mRNAs in higher eukaryotes 30 . While the other EJC proteins are not stably recruited to the C* complex, our structure nonetheless provides the first direct evidence for the location of EJC proteins in human spliceosomes and how they potentially interact with the exon RNA.
Repositioning of branched intron region
Directly after step one of splicing, the branched intron structure-that is, the U2/branch site helix in which the BS-A is covalently linked to the 5′ end of the intron-remains at the catalytic centre of the C complex, in part stabilized by the Cwc25, Yju2 and Isy1 proteins 21, 22 . Consistent with our purified C* complex representing a post-PRP16 stage, the branched intron structure is no longer positioned in the catalytic centre, but rather the phosphodiester bond between the BS-A and 5′ end of the intron is located approximately 20 Å away (Fig. 3a, b ).
This displacement distance is highly conserved between group IIB introns and the spliceosome 6 . In the C* EM density map, a helical density element extends from the U2/branch site helix, indicating formation of an extended, distorted helix between the U2 snRNA and nine intron nucleotides upstream of the branch site (that is, the extended U2/branch site helix) (Fig. 3b) . The latter is also formed in the yeast B act and C complexes and ILS 14, 20, 22 , and thus formation of this helix is a general feature, at least after spliceosome activation.
PRP8 and PRP17 stabilize the branch site position
The PRP8 RNase H-like (RH) domain is located at different positions in the B act , C, C* and ILS complexes (Extended Data Fig. 8 ). In C* , the RH domain interacts via its N-terminal α -helical region with extended α -helices close to the tip of the En domain of PRP8 (Fig. 3c) . At the same time, the RH domain's β -hairpin loop is inserted between the groove of the U2/branch site helix and the U6 ACAGA box/intron helix, contacting nucleotides of the U2 snRNA and the backbone of the U6 ACAGA sequence (Fig. 3a) . The branched intron structure rests on a basic region of the RH domain (Fig. 3c) . Thus the RH domain appears to play an important part in stabilizing the conformation of the branched intron structure in C* . Contact between the RH domain and the branched intron region also provides a potential structural basis for the suppression of BS-A mutations by RH domain mutants [31] [32] [33] ( Fig. 3d ). Like the RH domain, the PRP8 α -finger is also found in different positions in the B act , C and C* complexes. In C* the α -finger is located in the catalytic centre, suggesting that it may help to position the 3′ splice site for step two or, alternatively, that it might have to be repositioned to allow step two catalysis (Extended Data Fig. 8a, b) .
In the C* complex, the WD40 domain of the step-two factor PRP17 lies at a strategically important position between the U2 Sm core and PRP8 RH domain, close to the catalytic centre (Fig. 3c, e) . The WD40 domain contacts C-terminal helices and the β -hairpin loop of the PRP8 RH domain (Fig. 3c, d) , and the N-terminal region of CDC5 (Extended Data Fig. 9a, b) . The PRP17 WD40 domain also contacts the extended U2/branch site helix and U2 nucleotides that connect the extended U2/branch site helix with the putative U2 helix IIc (Fig. 3e , Extended Data Fig. 9c, d ). Consistent with its close interaction with U2 snRNA, mutations in the latter are lethal in the absence of Prp17 (ref. 34) . As both the RH domain of PRP8 and the U2 Sm core domain undergo PRP16-mediated remodelling (see below), the Prp17 WD40 domain may help stabilize the second-step conformation of the spliceosome, explaining its function as a second-step splicing factor 35 .
Remodelling during the catalytic phase
Although the structure of the central domain of the spliceosome does not change substantially during the catalytic steps of splicing, the U2 snRNP undergoes large-scale movements. In the C complex, the U2 Sm core, together with its attached Lea1 and Msl1 (human U2-A′ and U2-B′ ′ , respectively) proteins, has rotated and moved approximately 175 Å from its previous position in the B act complex (Fig. 4a) . This rearrangement requires destabilization of the U2 SF3a and SF3b proteins, which occurs during the Prp2-mediated catalytic activation of the B act complex 3, 36, 37 , and allows the U2/branch site helix to dock in the catalytic centre of the spliceosome. During PRP16-mediated transformation of the C complex into C* , the branched intron region moves away from the active site and the U2 Sm core moves approximately 100 Å, accompanied by a rotational movement (Fig. 4b) . The U2 snRNA contains four nucleotides (A29 to U32 in humans) located between the branch site interacting region and nucleotides that base pair with U6 to form U2/U6 helix Ia (Fig. 2b) , which could act as a hinge and allow these movements. Proteins that potentially aid in the repositioning of the U2 Sm core include SYF1 and SYF3. The N-terminal HAT repeats of SYF1 contact the U2 core domain via the U2-A′ protein both in C and C* , and regions of both SYF1 and SYF3 undergo movements in a concerted manner with the U2 Sm core domain (Fig. 4c) . The large-scale movements of the U2 Sm core domain may be driven by the repositioning 
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of the U2/branch site helix, as the rotational movements of the latter closely mirror those of the U2 Sm core (Fig. 4a, b) , with a similar distance between both elements observed at each stage (Fig. 4c) .
A comparison of the cryo-EM structure of the S. cerevisiae C complex (pre-Prp16 state) and the human C* complex (post-PRP16 state) reveals that an unexpectedly large number of RNA and protein domains are restructured during this PRP16-mediated transition of the spliceosome (Extended Data Fig. 10 ), assuming that the observed structural differences are not species-specific differences. These include repositioning of: (1) the extended branched intron structure; (2) the PRP17 WD40 domain; (3) the entire 3′ domain of U2 snRNP; (4) SYF1 and SYF3; (5) The RH domain and α -finger of PRP8; and (6) destabilization of Yju2 (CCDC130 in human) and Cwc25 (CWC25 in human) (refs 8, 38) . The high interconnectivity of these restructured domains suggests that their remodelling by PRP16 occurs in a coordinated manner. The PRP16-mediated movement of the branched intron away from the catalytic centre might initially be triggered by PRP16 destabilizing or repositioning one or more proteins (for example, [31] [32] [33] . e, Electrostatic surface potential of PRP17 WD40 and interactions with U2 snRNA and CypE.
Cwc25/CWC25 and Yju2/CCDC130), as opposed to acting directly on the branched RNA structure. The displacement of spliceosomal proteins probably creates new conformational space and enables the sampling of different RNP conformations within the spliceosome 39 . The resulting rearranged RNA/RNP conformation would then be stabilized by the formation of new protein-protein and protein-RNA interactions (for example, interaction of the branched intron with the PRP8 RH domain). A similar mechanistic principle can be envisioned for the RNP rearrangements in the spliceosome that are mediated by other spliceosomal helicases, such as PRP2 (ref. 19) .
Insights into the role of helicase PRP22
We do not find density to accommodate nucleotides containing the 3′ splice site, suggesting that it is flexible. For efficient positioning of the 3′ splice site in the catalytic centre, the second step factors SLU7, PRP18 and PRP22 are required (reviewed in ref. 40) . While SLU7 and PRP18 are missing from our C* complex, PRP22 is stoichiometrically present. The helicase domain of PRP22 fits into UPD3 of the C* unmasked EM density (Fig. 1) , where it is attached via its C-terminal oligonucleotide/ oligosaccharide-binding (OB) fold domain to the long α -helix of Skip and to the PRP8 RT domain (Fig. 5a) , consistent with earlier biochemical and genetic work [41] [42] [43] . As PRP22 contributes to step two of splicing in an ATP-independent manner 11 and is located far from the C* catalytic centre (Fig. 5b) , it probably plays an indirect role in positioning the 3′ splice site for catalysis of step two. Following catalytic step two, PRP22 facilitates the release of the spliced mRNA in an ATPdependent manner 44 . To achieve this, PRP22 may have to undergo a conformational change in order to bind the spliced 3′ exon, which is required for its activity 45 . As CWC22 is located on both sides of the exon-binding channel, its removal may be a prerequisite for release of the spliced mRNA from the latter. Indeed, during mRNA release from the post-step two spliceosome, there is nearly quantitative displacement of CWC22 (ref. 46) . PRP22 is bound close to the region of the PRP8 RT domain where the MA3 domain of CWC22 is located (Fig. 5b) , and thus its action might potentially lead to displacement of CWC22. PRP2, PRP16 and PRP22, which bind transiently and in a sequential manner, are all located at the periphery of their respective spliceosomal complexes, at a distance from their presumed targets, which are located at or near the catalytic centre (Fig. 5c) . Thus, all three helicases appear to act indirectly, at a distance, as recently proposed for PRP2 (ref. 19) and PRP16 (ref. 47) .
A comparison of the cryo-EM structures of the human C* and S. pombe ILS indicates that the rearrangements accompanying this transition are more subtle than those occurring during the C to C* transition. However, determination of the structures of the human B act , C and ILS complexes will be needed to clarify whether structural changes proposed to occur during splicing catalysis are indeed evolutionarily conserved.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. In vitro splicing. Uniformly [ 32 P]-labelled, m 7 G(5′ )ppp(5′ )G-capped MINX pre-mRNA was synthesized in vitro by T7 runoff transcription. HeLa S3 cells were obtained from GBF, Braunschweig (currently Helmholtz Zentrum für Infektionsforschung, Braunschweig) and tested negative for mycoplasma. HeLa nuclear extract was prepared essentially as previously described 48 , but without the final dialysis step. To isolate C* complexes, splicing was performed with 5 nM of 32 P-labelled pre-mRNA and 20% (v/v) HeLa nuclear extract, in buffer containing 3 mM MgCl 2 , 50 mM NaCl, 4 mM HEPES-KOH pH 7.9, 12 mM MES-NaOH pH 6.4, 2 mM ATP and 20 mM creatine phosphate, and was incubated at 30 °C for different time periods. Samples were analysed on a denaturing 4-12% NuPAGE gel (Life Technologies) and pre-mRNA and splicing intermediates and products were visualized with a Typhoon phosphorimager (GE Healthcare). MS2 affinity selection of splicing complexes. Spliceosomal complexes were isolated by MS2 affinity selection. In previous studies, affinity purified human C complexes were formed in vitro on mutated pre-mRNA substrates that are unable to undergo the second step of splicing [49] [50] [51] . Here, we used the MINX premRNA substrate 52 that contains an intron flanked by a 5′ and 3′ exon, allowing a functional analysis of complexes that assemble on it. In brief, MINX pre-mRNA containing three MS2 aptamers at its 3′ end RNA was incubated with a tenfold molar excess of MS2-MBP fusion protein and then added to a splicing reaction. After incubating at 30 °C for 5 h and centrifuging to remove aggregates, the reaction was loaded onto a MBP Trap HP column (GE Healthcare) after addition of 5 mM HEPES-KOH pH 7.9. The column was washed with G-150 buffer (20 mM HEPES-KOH pH 7.9, 1.5 mM MgCl 2 , 150 mM NaCl) and complexes were eluted with G-150 buffer containing 1 mM maltose. Eluted complexes were loaded onto a 36 ml linear 10-30% (v/v) glycerol gradient containing G-150 buffer (20 mM HEPES-KOH pH 7.9, 1.5 mM MgCl 2 , 150 mM NaCl), centrifuged at 23,000 r.p.m. for 15 h at 4 °C in a Surespin 630 (Thermo Scientific) rotor and fractions were harvested from the bottom. The distribution of 32 P-labelled MINX RNA across the gradient was determined by Cherenkov counting. Fractions were analysed by denaturing 4-12% NuPAGE (Life Technologies) followed by autoradiography. Peak fractions containing the first step splicing intermediates were pooled, concentrated by centrifugation with an Amicon 50 kD cut-off unit, diluted to decrease the glycerol concentration and reloaded on the same gradients with glutaraldehyde as fixative 53 . For biochemical sample validation, the same procedure was performed but without fixation in the second gradient. The RNA and protein compositions of purified complexes were determined by denaturing 1D PAGE and 2D gel electrophoresis. 2D gel electrophoresis and mass spectrometry. Two-dimensional gel-electrophoresis of affinity-purified spliceosomal complexes was performed as described in ref. 54 , using a 7% acrylamide mono gel in the second dimension for analysis of proteins larger than 25 kDa, or 15% acrylamide for proteins smaller than 25 kDa. For mass spectrometry, coomassie-stained protein-spots were cut out of the 1D or 2D gels, and proteins were digested in-gel with trypsin and extracted. The extracted peptides were analysed in a liquid-chromatography coupled electrospray ionization mass spectrometer (LTQ Orbitrap XL) under standard conditions. Proteins were identified by searching fragment spectra against the NCBI non-redundant (nr) database using Mascot as a search engine. Chase of purified C* complexes with nuclear extract. Total IgGs against human PRP16 were purified as described previously 55 . Affinity-purified C* complexes formed on 32 P-labelled MINX-MS2 pre-mRNA were incubated with splicing buffer alone (20 mM HEPES-KOH pH 7.9, 50 mM NaCl, 3 mM MgCl 2 , 2 mM ATP, 20 mM creatine phosphate) or additionally in the presence of 20% HeLa nuclear extract prepared according to ref. 48 . For antibody inhibition experiments, the splicing mixture was pre-incubated with 3 μ g μ l −1 of anti-PRP16 antibody at 30 °C for 15 min as described 55 . The splicing reaction was initiated by addition of 32 P-labelled MINX-MS2 pre-mRNA or C* complex assembled on 32 P-labelled MINX-MS2 pre-mRNA. The reaction was incubated at 30 °C for 0-60 min. RNA was recovered, separated by SDS-PAGE, and visualized with a Typhoon phosphorimager (GE Healthcare). Crosslinking of the C* complex and crosslink identification. Following MS2 affinity selection and the first density gradient centrifugation step, purified spliceosomal complexes were crosslinked with 150 μ M BS3 for 40 min at 20 °C and purified further by a second density gradient centrifugation step. Approximately 25 pmol of C* complexes were pelleted by ultracentrifugation and analysed essentially as described before 56 with the following modifications: precipitated material was dissolved in a solution containing 4 M urea and 50 mM ammonium bicarbonate, reduced with DTT, alkylated with iodoacetamide, diluted to 1 M urea and digested with trypsin (1:20 w/w). Peptides were reverse-phase extracted and fractionated by gel filtration on a Superdex Peptide PC3.2/30 column (GE Healthcare). 50-μ l fractions corresponding to an elution volume of 1.2-1.8 ml were analysed in quadruplicate on a Thermo Scientific Q Exactive HF mass spectrometer. Protein-protein crosslinks were identified by pLink 1.23 search engine (http:// pfind.ict.ac.cn/software/pLink) and filtered at FDR 1% according to the recommendations of the developer 57 . For simplicity, the crosslink score is represented as a negative value of the common logarithm of the original pLink score, that is Score = -log 10 (pLink Score). For model building, a maximum distance of 30 Å between the Cα atoms of the crosslinked lysines was allowed. Approximately 97% of all crosslink-assigned spectra correspond to crosslink distances of 30 Å or less. EM and image processing. Purified spliceosomes, stabilized by GraFix 53 , were allowed to adsorb on a thin carbon film before negative staining or rapid plunge freezing into liquid ethane at 100% humidity and 4 °C. Micrographs of negatively stained particles were recorded in a CM200 electron microscope (FEI/Phillips, the Netherlands) at room temperature and approximately 50,000 particles were picked by hand. The latter were then used to de novo build a negative stain starting structure that was refined to around 25 Å by using 3D maximum-likelihood alignment and 3D classification 58 . The resulting model was subsequently used as an initial reference in cryo-particle image processing and classification. Cryo-images were recorded at − 193 °C in a Titan Krios electron microscope (FEI Company, The Netherlands) on a Falcon II direct electron detector at a nominal 88,000× magnification resulting in a calibrated pixel size of 1.59 Å on the specimen level. Seventeen frames were recorded for each micrograph with an average dose of 2.1 e − per frame per Å 2 . Motion correction and spatial frequency weighed frame summation was achieved using the unblur software suite 59 (http://grigoriefflab.janelia.org/unblur). Summed micrograph images were then evaluated based on CTF parameters and only those revealing isotropic Thon rings were used for particle picking and extraction. Using the particle picking software Gautomatch (http://www.mrc-lmb.cam. ac.uk/kzhang/) and 40° projections of the negative stain model filtered to 40 Å as a reference, we extracted approximately 2.5 million particle images from the pre-sorted cryo-micrographs and applied several particle sorting steps at the 2D and 3D level. 2D multivariate statistics and classification was first applied to the non-aligned particle images and subsequently to the aligned particles. In each round, particles contributing to bad classes were excluded from further processing. The remaining ~ 1,708,000 particles were split into seven equally sized groups and subsequently applied to seven separate rounds of 3D classification in RELION featuring six classes each. The ~ 393,000 particles pooled from all satisfactory classes were then subjected to further rounds of 3D classification in RELION 71 . For the high resolution structure determination, the 136,534 particles finally contributing to the best 3D class were used for refinement revealing an 8.4 Å resolution structure (which we refer to as the unmasked EM density map). Roughly 20% of the spliceosome density was not clearly defined at this level of resolution. As these densities largely disappear during the higher-resolution structure calculations, we excluded them with a mask in the final rounds of the refinement. A soft mask with a cut-off of 7 voxels was used for the refinement and for the determination of resolution. We obtained the final map with a resolution of 5.9 Å as determined by Fourier shell correlation calculated from two independent data sets with a threshold of 0.143. A local resolution plot revealed that there are areas of higher resolution in the catalytic RNP core of the C* complex that approach 4.5 Å. Some peripheral regions have somewhat lower resolution ( Fig. 1 and Extended Data Fig. 2c ). More dynamic areas or those with components with non-stoichiometric occupancies are not visible in the 5.9 Å structure. Model fitting and building. Available X-ray or homology models of proteins were fit into the EM density by Chimera 60 . Individual models of substructures (for example, domains or structural motifs) were further fitted as rigid bodies by Coot 61 . After visual inspection, the models were adjusted manually in the density, the disordered regions were removed and regions that were reorganized or were not present in the initial models (for example, loops and various elements of secondary structure) were built in Coot. Homology models of proteins were either obtained by using the respective functions of the SWISS-MODEL suite 62 or directly adapted from the SpliProt3D database 63 . Initial human snRNA and intron models were obtained by using the S. cerevisae C complex spliceosomal RNA 14, 21 as reference, and homology modelled according to the human sequence using the ModeRNA package 64 (http://genesilico.pl/moderna/). The snRNA fit was improved at rigid body level in Chimera and subsequently adjusted in Coot. The 5′ stem loop of U6 and the U2/U6 helix II were generated by rigid-body fitting of idealized double-stranded RNA helices. Exon 1 was modelled ab initio into available density in Coot and the resulting model later verified by comparison to the S. cerevisiae C spliceosome model 22 . Once the entire coordinate model was built up, all proteins were truncated to poly-alanine level and a global minimization real space refinement was conducted against the 5.9 Å cryo-EM density using the real space refine and protein (c) composition of MS2 affinity-purified, human C* complexes. Only high molecular weight proteins are labelled. C* complexes contained predominantly the first-step splicing intermediates (cleaved 5′ exon and the lariat-3′ -exon), and U2, U5 and U6 snRNA. d, e, Abundant C* proteins (red) identified by 2D gel electrophoresis, summarized in e. Less abundant proteins, green. Upper and lower panel: proteins > 25 kDa or < 25 kDa, respectively. Proteins present in substoichiometric amounts in previous human C complex preparations (for example, SF3a and SF3b proteins) 49, 51 were lacking or present only in very low amounts. SRm300 does not migrate well into the second dimension of the 2D gel, but is clearly observed on a 1D gel. The steptwo factors SLU7 and PRP18 were not detected, which may explain why spliceosomes are stalled after step one at pH 6.4. All abundant proteins or domains/regions thereof were modelled into the C* EM density map, except BRR2, ISY1, NY-CO-10, CCD12, PPIL3, CBP80 and CBP20 (Supplementary Table 1 ). As BRR2 could not be located in the C* EM density map, it is probably highly flexible in C* . f, C* complexes formed on 32 P-labelled MINX pre-mRNA at pH 6.4 were purified and incubated in HeLa nuclear extract at pH 7.9 or in buffer under splicing conditions. Splicing intermediates were efficiently chased into splicing products after 15 min in the presence of nuclear extract, but not buffer alone, indicating that our purified C* complexes are functional and not dead-end complexes. g, h, MINX pre-mRNA (g) or affinity-purified C* complexes (h) were incubated with HeLa nuclear extract with or without anti-PRP16 antibodies. Efficient catalysis of step two of splicing was observed if purified C* complexes, but not pre-mRNA alone, were incubated in nuclear extract pre-incubated with PRP16 antibodies, indicating that the C* complexes are indeed stalled after the action of PRP16. All 2D analyses and in vitro splicing experiments were performed at least twice in two independent experiments. At the interface between SYF1 and aquarius there is a density element that accommodates cyclophilin E (CypE), a spliceosomal protein not found in yeast (Fig. 1) . In C* , the density accommodating aquarius is less well-defined, presumably owing to flexibility of this part of the complex. Crosslinks between ISY1 and aquarius indicate that part of ISY1 is located at the top of C* (Supplementary Table 2 ). The meandering path of Skip (Prp45) and Ad002 (Cwc15) around the PRL1 WD40 domain is shown. N-terminal parts of Skip and Ad002 also contact the U6 ISL (see also Extended Data Fig. 3 ). The position of the PRP19 helical bundle (containing SPF27, the C-terminal part of CDC5 and four copies of PRP19) is stabilized by interactions of the C-terminal end of CDC5 with the WD40 domain of the U5-40K protein, and by interactions with the cyclophilin PPIL1. The WD40 domains of PRP19 are not visualized, presumably owing to their flexibility. N or C, N or C terminus. b, Magnified view showing the fit of parts of SYF1, SYF2 and SYF3 and their neighbouring proteins into the C* EM density map. In C* , the C-terminal HAT repeats of SYF1 contact the N-terminal Myb domain of CDC5 (which in turn binds to the PRP8 RT domain). CDC5 α -helix 2 runs along the U6 ACAGA box/intron helix. c, Fit of Skip, PRL1, Ad002, SYF2 and their neighbouring proteins into the C* EM density map. Major parts of Skip (amino acid numbers shown in red) bridge the WD40 domain of PRL1 (Prp46 in S. cerevisiae) and SYF3 N-terminal HAT repeats 2-5 with the PRP8 NTD2. SYF2 (amino acid numbers in blue) contacts U2/U6 helix II. The N-terminal part of Ad002 (amino acid numbers in pink) contacts the PRL1 WD40 domain (see also panel f). d, e, Comparison of the structure/organization of SYF1 and SYF3 (shown as space filling models), aquarius and other NTC and NTC-related proteins in the human C* complex and the S. pombe ILS. The N-terminal region of CDC5, the N-terminal α -helices of SYF3, WD40 domain of PRL1, major parts of Skip and Ad002, and PPIL1 (Ppi1 in S. pombe) have nearly the same structure and position as their yeast homologues (see also panels a-c). f, N-terminal amino acids of Skip interact with PPIL1, consistent with previous biochemical and structural studies [67] [68] [69] . Figure 7 | Location and structure of CWC22 and its interaction partner, the EJC helicase eIF4AIII, in the C* complex. a, EM density fit of various proteins forming the channel in which the 5′ exon is bound. The MA3 domain of CWC22 binds the PRP8 RT/En domain and its N-terminal MIF4G domain is attached to domain 1 of SNU114. The MIF4G domain is only clearly visible in the unmasked EM density of the C* complex, and maps to UPD2 (panel a and b) . The PRP8 switch loop is shown in light blue. Close to the PRP8 switch loop, there is a density element into which the approximately 20 N-terminal amino acids of SRm300 can be accommodated in a manner similar to the arrangement of the homologous sequence of Cwc21 in the C complex of S. cerevisiae (indicated in green colour). b, EM density fit of the CWC22 MIF4G domain and the RecA domains of the eIF4AIII RNA helicase in the UPD2 density of the unmasked C* model. Consistent with crosslinks (Supplementary Table 2 ), the RecA2 domain contacts the MIF4G domain. In the C* complex, the relative orientation of the two RecA domains is such that they adopt a partially closed conformation, in contrast to their open (inactive) conformation in the MIF4G-eIF4AIII co-crystal structure (middle panel; PDB 4C9B) and their closed conformation in the crystal structure of the EJC complex, in complex with RNA (right most panel; PDB 2XB2). Shown is the poor fit of the RecA1 domain when in the open or completely closed conformation. Protein crosslinks between eIF4AIII and an N-terminal region of SRm300 indicate that part of this region is located in the neighbouring UPD1 density element of the unmasked C* complex map, adjacent to domain 4 of SNU114 (which is not a part of UPD1), consistent with the location of two α -helical elements of Cwc21 in an equivalent position in the S. cerevisiae C complex 22 . We cannot locate the RS domain of SRm300, probably because it is very flexible and located at the periphery of the C* complex. c, Model of the position of an extended 5′ exon RNA (red) relative to the RecA domains of eIF4AIII in the C* complex. Extension of the 5′ exon RNA to position − 26 (relative to the 5′ splice site) was performed by inserting nucleotides − 26 to − 18 based on the crystal structure of the isolated EJC bound to RNA and additionally modelling in exon nucleotides − 17 to − 13 (in an extended conformation), which we cannot clearly localize based on the EM density map. This suggests that eIF4AIII is already located at an optimal distance (that is, around 20 nucleotides upstream) from the 5′ splice site (and thus also from the exon-exon junction that is formed after step two of splicing). Tight binding of eIF4AIII to the 5′ exon probably occurs at a stage after formation of the C* complex, based on the observation that the RecA domains are not completely closed at this stage.
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